Vaissière Thomas, Cuenin Cyrille, Paliwal Anupam, Vineis Paolo, Hoek G, Krzyzanowski M, Airoldi L, Dunning A, Garte S, Hainaut P, Malaveille C, Overvad K, Clavel-Chapelon F, Linseisen J, Boeing H, Trichopoulou A, Trichopoulos D, Kaladidi A, Palli D, Krogh V, Tumino R, Panico S, Bueno-De-Mesquita H B, Peeters P H, Kumle M, Gonzalez C A, Martinez C, Dorronsoro M, Barricarte A, Navarro C, Quiros J R, Berglund G, Janzon L, Jarvholm B, Day N E, Key T J, Saracci R, Kaaks R, Riboli E, Hainaut Pierre, Herceg Zdenko
International Agency for Research on Cancer (IARC), Lyon F-69008, France.
Epigenetics. 2009 May 16;4(4):221-30. doi: 10.4161/epi.8833. Epub 2009 May 24.
Cell-free circulating DNA isolated from the plasma of individuals with cancer has been shown to harbor cancer-associated changes in DNA methylation, and thus it represents an attractive target for biomarker discovery. However, the reliable detection of DNA methylation changes in body fluids has proven to be technically challenging. Here we describe a novel combination of methods that allows quantitative and sensitive detection of DNA methylation in minute amounts of DNA present in body fluids (quantitative Methylation Analysis of Minute DNA amounts after whole Bisulfitome Amplification, qMAMBA). This method involves genome-wide amplification of bisulphite-modified DNA template followed by quantitative methylation detection using pyrosequencing and allows analysis of multiple genes from a small amount of starting DNA. To validate our method we used qMAMBA assays for four genes and LINE1 repetitive sequences combined with plasma DNA samples as a model system. qMAMBA offered high efficacy in the analysis of methylation levels and patterns in plasma samples with extremely small amounts of DNA and low concentrations of methylated alleles. Therefore, qMAMBA will facilitate methylation studies aiming to discover epigenetic biomarkers, and should prove particularly valuable in profiling a large sample series of body fluids from molecular epidemiology studies as well as in tracking disease in early diagnostics.
从癌症患者血浆中分离出的游离循环DNA已被证明存在与癌症相关的DNA甲基化变化,因此它是生物标志物发现的一个有吸引力的靶点。然而,可靠检测体液中的DNA甲基化变化在技术上具有挑战性。在此,我们描述了一种新的方法组合,该方法能够对体液中微量DNA的甲基化进行定量和灵敏检测(全亚硫酸氢盐组扩增后微量DNA的定量甲基化分析,qMAMBA)。该方法包括对亚硫酸氢盐修饰的DNA模板进行全基因组扩增,然后使用焦磷酸测序进行定量甲基化检测,并允许从少量起始DNA中分析多个基因。为了验证我们的方法,我们将qMAMBA检测用于四个基因和LINE1重复序列,并结合血浆DNA样本作为模型系统。qMAMBA在分析DNA含量极少且甲基化等位基因浓度低的血浆样本中的甲基化水平和模式方面具有高效性。因此,qMAMBA将有助于旨在发现表观遗传生物标志物的甲基化研究,并且在分析分子流行病学研究中的大量体液样本系列以及早期诊断中追踪疾病方面应具有特别重要的价值。